Can-Fite plummets as novel compound disappoints once again
This article was originally published in Scrip
Executive Summary
The Israeli company Can-Fite BioPharma's Phase II/III trial of its lead product CF101 has failed to meet its primary endpoint in moderate-to-severe plaque psoriasis. This was the second major failure for the product, a first-in-class A3 adenosine receptor agonist, after disappointment in a Phase III trial in dry eye syndrome at the end of 2013, and shares in the firm on the New York Stock Exchange dropped by 60% to close at $2.20 on 30 March.
You may also be interested in...
Can-Fite Plans Phase III For Namodenoson, Despite Liver Cancer Trial Failure
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.